Cantor Fitzgerald lowered its price target for Eli Lilly and Company following data related to its obesity medicines.
1 report, 1 independent
Updated Aug 16
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Cantor Fitzgerald lowered its price target for Eli Lilly and Company following data related to its obesity medicines.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Eli Lilly and Company
American pharmaceutical company
-
Cantor Fitzgerald
American financial services company
Related events
- Eli Lilly and Kailera Therapeutics are competing in the obesity treatment market.
- Eli Lilly and Company has achieved market leadership in the obesity and diabetes treatments sector.
- Eli Lilly, Novo Nordisk, and Merck are currently competing in the highly competitive GLP-1 obesity market.
- Cantor Fitzgerald, Morgan Stanley, and Royal Bank of Canada issued price target updates for Elevance Health, Inc. on September 12, 2026.
- Cantor Fitzgerald raised its price target on Salesforce on September 1, 2026.
Coverage
Newest first; wire copies grouped- Insider MonkeyCantor Fitzgerald Slashes PT on Eli Lilly and Company (LLY) to $825 From $975 Eli Lilly and Company (NYSE:LLY) is one of the best stocks to invest in for beginners. On August 13, Cantor Fitzgerald an